uniQure's AMT-130 Regulatory Uncertainty Sparks Hope for Huntington’s Disease
TL;DR
uniQure announced that the FDA no longer considers Phase I/II data versus an external control sufficient as primary evidence for a BLA submission for its Huntington's disease gene therapy AMT-130, creating uncertainty about the approval timeline. The company plans urgent discussions with the FDA and continues regulatory engagement in the EU and UK, despite holding breakthrough therapy and RMAT designations.
- uniQure (NASDAQ: QURE) updates on AMT-130; FDA feedback shifts, BLA timing unclear Stock Titan
- uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease Yahoo Finance
- Uniqure’s FDA submission for its Huntington’s disease therapy thrown into question statnews.com
- October 2025: This Month in Huntington’s Disease Research HDBuzz
- Hope for Huntington’s Sufferers God's World News
Want the full story? Read the original reporting
Read on Stock Titan